Track topics on Twitter Track topics that are important to you
Nivalis Therapeutics Inc Nivalis Therapeutics, formerly N30 Pharmaceuticals is a pharmaceutical company that develops a novel class of disease modifying therapies, which can preserve intracellular GSNO in the pathophysiology of cystic fibrosis. The company also carries out the discovery, development and commercialization of snitrosothiol drugs. It offers products for the treatment of respiratory and cardiopulmonary diseases such as cystic fibrosis, asthma and chronic obstructive pulmonary disease. Nivalis Therapeutics' N91115 targets patients with the F508del mutation, which is the common disease causing mutation in cystic fibrosis. The company has developed small molecule inhibitors of the Snitrosoglutathione reductase protein that can increase CFTR activity and decrease airway inflammation. Nivalis Therapeutics is headquartered in Boulder, Colorado, the US.
Nivalis Therapeutics Inc Key Recent Developments
Nov 07, 2016: Nivalis Therapeutics Reports Third Quarter 2016 Financial Results
Nov 03, 2016: Nivalis Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
Aug 01, 2016: Nivalis Therapeutics Reports Second Quarter 2016 Financial Results
May 02, 2016: Nivalis Therapeutics Reports First Quarter 2016 Financial Results
Apr 18, 2016: Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery
This comprehensive SWOT profile of Nivalis Therapeutics Inc provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Nivalis Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends.
The profile contains critical company information including*, x000D
Business description A detailed description of the company's operations and business divisions.x000D
Corporate strategy Analyst's summarization of the company's business strategy.x000D
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.x000D
Company history Progression of key events associated with the company.x000D
Major products and services A list of major products, services and brands of the company.x000D
Key competitors A list of key competitors to the company.x000D
Key employees A list of the key executives of the company.x000D
Executive biographies A brief summary of the executives' employment history.x000D
Key operational heads A list of personnel heading key departments/functions.x000D
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.x000D
Key manufacturing facilities A list of key manufacturing facilities of the company.x000D
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.x000D
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.x000D
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,x000D
You get detailed information about the company and its operations to identify potential customers and suppliers.x000D
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.x000D
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.x000D
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. x000D
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.x000D
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.x000D
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.x000D
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.x000D
Gain key insights into the company for academic or business research.x000D
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...